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Graft-versus-Host Disease following Allogeneic
Transplantation: Preventive Effect of Vascular
Endothelial Growth Factor Gene on Acute
Graft-versus-Host Disease
Dong Hwan Kim,1,4 Nan Young Lee,2 Myung-Hoon Lee,3 Sang Kyun Sohn1Microvessel injury is associated with the development of graft-versus-host disease (GVHD), whereas high
levels of posttransplantation vascular endothelial growth factor (VEGF) have a protective effect on severe acute
GVHD (aGVHD) and transplantation-related mortality. The current study aimed to determine the impact of
VEGFA gene single-nucleotide polymorphisms (SNPs) on the riskof aGVHD after allogeneic stem cell transplan-
tation (SCT). Using polymerase chain reaction and restriction fragment length polymorphism, 4 VEGFA SNPs—
-2578 C.A (rs699947), -460 T.C (rs833061),1405 G.C (rs2010963), and1936 C.T (rs3025039)—were
analyzed in 98 recipients. Strong linkage disequilibrium was noted among loci -2578, -460, and1405, but not
among these loci and locus1936. Accordingly, 4 haplotypes were generated based on the genotypes of -2578,
-460, and1405: CTC (47.9%), CTG (26.7%), ACG (24.2%), and CCC (1.0%). The group with low VEGF pro-
duction (ie,1936CT genotype and 2 copies of the ACG haplotype) had a higher incidence of aGVHD. Signif-
icant associations were found between the risk of grade 2-4 aGVHD and the1936 CT (P5 .006), -2578 AA
(P5 .003), and -460 CC (P5 .002) genotypes and the ACG haplotype (P5 .003). No association between the
VEGFA SNPs and chronic GVHD was observed. The VEGFA SNPs might predict a lower risk of aGVHD. Our
findings suggest that VEGF may have a protective role in the pathogenesis of aGVHD.
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The pathogenesis of graft-versus-host disease
(GVHD) has yet to be fully elucidated, although it
is generally accepted that alloreactive T cell cytotox-1Departments of Hematology/Oncology; 2Laboratory
ine; 3Biochemistry, Kyungpook National University
ital, Daegu, Korea; and 4Department of Hematology/On-
y, Samsung Medical Center, Sungkyunkwan University
l of Medicine, Seoul, Korea.
isclosure: See Acknowledgments on page 1415.
at the European School of Hematology Euroconference
anslational Research in Transplantation, Integrating Im-
y: From Genomics to Cell Therapy, Leiden, The Nether-
November 2007.
dence and reprint requests: Dong Hwan Kim, MD, PhD,
rtment of Hematology/Oncology, Samsung Medical
r, Irwon-dong 50, Kangnam-gu, Sungkyunkwan Univer-
chool of Medicine, Seoul, Korea, 135-710 () (e-mail:
@medimail.co.kr).
ay 18, 2008; accepted September 24, 2008
/08/1412-0001$34.00/0
6/j.bbmt.2008.09.022icity is a central mediator. Alloreactive T cells recog-
nize the recipients’ target tissues as nonself and evoke
GVHD. The final step in the development of GVHD
occurs in targeted tissues, in which inflammation
develops due to interactions between these tissues
and cytotoxic T cells. It An association between these
inflammatory reactions and angiogenesis is well
established.
Recently, endothelialitis and subsequent microves-
sel injury were found to be involved in the pathogene-
sis of GVHD. One study found strikingly higher
microvessel densities in skin samples in healthy normal
donors than in patients with acute GVHD (aGVHD)
or chronic GVHD (cGVHD). Accordingly, it has
been suggested that the endothelium is targeted during
GVHD and that microvessel injury is a consequence of
perivascular inflammation and endothelial cell death,
which results in progressive microvessel loss and con-
sequent tissue ischemia and stimulates the production
of VEGF [1]. Accordingly, angiogenesis also is in-
volved in the pathogenesis of GVHD.
Table 1. Patient Characteristics and Transplantation Pro-
cedures
Variable No. of pts (%)
Recipients
Sex, female/male, n (%) 34/64 (35/65)
Age, years, median (range) 33 (16 to 58)
Diagnosis
AML/ALL 50/11 (51/11)
CML/MDS 14/4 (14/4)
SAA/NHL 10/8 (10/8)
Solid tumor* 1 (1)
Advanced disease 48 (49)
Donors
Biol Blood Marrow Transplant 14:1408-1416, 2008 1409VEGF Gene SNPs and the Risk of Acute GVHDVEGF, a soluble 34- to 46-kDa heparin-binding
glycoprotein dimer, is a potent angiogenic peptide
with diverse biological activities that include angiogen-
esis in both physiological and pathological situations
[2]. VEGF gene (VEGFA) expression is regulated by
various growth factors, cytokines, and hormones, as
well as by hypoxia [3]. VEGF can be produced by nu-
merous cells, including lymphocytes, macrophages,
vascular smooth muscle cells, fibroblasts, keratinocytes,
megakaryocytes, neutrophils, basophils, and mast cells.
Moreover, previous investigations have suggested that
type 2 cytokine stimulates VEGF production [4,5].
Interestingly, higher VEGF levels at day 14 or 15
posttransplantation have been suggested to protect
against the development of severe GVHD [4,6]. The
first study to investigate this concept found an associ-
ation between high VEGF levels and a lower incidence
of nonrelapse-related mortality (NRM) (23% vs 4%),
along with an inverse correlation between VEGF
levels at day 14 posttransplantation with the severity
of aGVHD [4]. Moreover, patients with severe grade
3-4 aGVHD had significantly lower log-transformed
VEGF levels than those with or without grade 1-2
aGVHD [4]. Another study similarly reported im-
proved survival in patients with higher VEGF levels
at day 15 posttransplantation [6]. These 2 studies sug-
gest that VEGF protects against severe aGVHD.
Recent investigations have demonstrated that
VEGFA polymorphisms contribute to interindividual
variations in VEGF expression. TheVEGFA gene is lo-
cated on chromosome 6p21 and consists of 8 exons and
7 introns [7,8]. Furthermore, polymorphisms in its
promoter region (loci -2578C.A [rs699947] and
-460T.C [rs833061]), its 5´-untranslated region
(1405C.G [rs2010963]) and its 3´-untranslated region
(1936C.T [rs3025039]) have been associated with dif-
ferent levels of VEGF expression [9-14]. Accordingly, in
the present study, we investigated the impact ofVEGFA
polymorphisms on the development of aGVHD on out-
come after allogeneic stem cell transplantation (SCT).Sex, female/male, n (%) 34/64 (35/65)
Age, years, median (range) 34 (15 to 65)
Conditioning, n (%)
BuCy 57 (58)
CyATG 10 (10)
Fludarabine-based RIST 31 (32)
Infused cell
dose, median
MNCs,  108/kg 6.75
CD34+ cells,  106/kg 6.32
CD3+ cells,  108/kg 1.97
GVHD prophylaxis, n (%)
CSA/MTX 86 (88)
CSA 6 (6)
FK506/sMTX 6 (6)
ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia;
MDS, myelodysplastic syndrome; SAA, severe aplastic anemia; NHL,
non-Hodgkin lymphoma; BuCy, busulfan/cyclophosphamide; CyATG,
cyclophosphamide/ATG; RIST, reduced-intensity conditioning stem cell
transplantation; MNC, mononuclear cell; sMTX, short-term MTX.
*Metastatic colorectal carcinoma.MATERIALS AND METHODS
The objective of the present study was to investi-
gate an association between VEGFA polymorphisms
and the development of aGVHD or cGVHD after al-
logeneic SCT.
Patient Characteristics and Transplantation
Procedure
Ninety-eight consecutive patients who had re-
ceived an HLA-matched sibling transplant at the
Kyungpook National University Hospital, Daegu,
Korea between August 1998 and June 2005 were in-
cluded in this retrospective study. Detailed informa-
tion is provided in Table 1. The conditioningregimens consisted of busulfan/cyclophosphamide (n5
57; 58%), fludarabine-based regimens (n 5 31; 32%),
and cyclophosphamide/antithymocyte globulin (ATG)
(n 5 10; 10%). All 98 patients received peripheral
blood stem cells (PBSCs), as described previously
[15]. GVHD prophylaxis included cyclosporin A
(CSA) plus methotrexate (MTX) in 86 patients
(88%) and CSA alone or FK506/MTX in 6 patients
each (6%/6%). Treatment for aGVHD and cGVHD
was provided according to a standard protocol, as
described previously [16].Genotyping of VEGFA and Genotype Analysis
For VEGFA genotyping, genomic DNA was ex-
tracted from peripheral blood using the Wizard geno-
mic DNA purification kit (Promega, Madison, WI).
The VEGF -2578C.A (rs699947), -460T.C
(rs833061), 1405C.G (rs2010963), and 1936C.T
(rs3025039) genotypes were determined by polymer-
ase chain reaction (PCR) and restriction fragment
length polymorphism, as described previously [17-
20]. To confirm genotyping results, selected PCR-am-
plified DNA samples (n 5 2 for each genotype) were
examined by DNA sequencing [17]. The study design
was approved by the Kyungpook National University
Hospital Institutional Research Board and conformed
1410 Biol Blood Marrow Transplant 14:1408-1416, 2008D. H. Kim et al.to the Helsinki Declaration. Each patient provided
written informed consent.
Four genotypes were evaluated using the c2 test to
determine whether they conformed with the Hardy-
Weinberg equilibrium (HWE). Genotype frequencies
were determined using Haploview software (available
at http://www.broad.mit.edu/mpg/haploview). Addi-
tive, dominant, and recessive models were used to in-
vestigate associations between each single-nucleotide
polymorphism (SNP) and transplantation outcomes.
Haplotype analysis for deviation from the HWE was
conducted, and haplotype frequencies were estimated
using linkage disequilibrium (LD) coefficients, D´. Indi-
vidual haplotypes were determined with a Bayesian al-
gorithm using the Phase program (available at http://
www.stat.washington.edu/stephens/phase.html) [21].
As in our previous study [20], here a VEGF risk
score model was generated based on the genotype at lo-
cus1936 and the copy number of the ACG haplotype
at loci -2578/-405/1460. A score of 1 was assigned to
risk alleles (ie,1936 CT or TT genotypes, or 2 copies
of the ACG haplotype), and a score of 0 was assigned to
other alleles (ie, the1936 CC genotype, or 0 or 1 copy
of the ACG haplotype). The scores were summed, and
2 risk groups were defined: high risk (composite score,
2 or 1) and low risk (composite score, 0).
Definition and Endpoints
The day of stem cell infusion was defined as day 0.
Engraftment was confirmed by peripheral blood
counts, that is, a peripheral absolute neutrophil count
of . 0.5 109/L and a peripheral platelet count of .
20  109/L for at least 3 consecutive days without re-
quiring transfusion. Overall survival (OS) was defined
as the time from transplantation until death from any
cause. aGVHD and cGVHD were diagnosed and
graded based on established criteria [22,23].
Statistical Analysis
The data were analyzed according to information
available on July 2005. The clinical characteristics
and transplantation outcomes of patients were com-
pared using the c2 test, Fisher’s exact test, or the
Mann-WhitneyU test for differentVEGFA genotypes.
Probabilities of OS were calculated and plotted us-
ing the Kaplan-Meier method. The incidences of
aGVHD, cGVHD, NRM, and recurrence were esti-
mated using the cumulative incidence method consid-
ering competing risks [24]. During single-marker
analyses, the OSs of VEGFA SNPs were compared us-
ing additive, dominant, and recessive models through
the log-rank test, whereas the incidences of aGVHD,
cGVHD, NRM, and recurrence for different VEGFA
SNPs were compared using Gray’s test.
During multivariate analyses using Cox propor-
tional hazard models, clinical factors and significantgenotypes were considered as covariates for each
event. Because our analysis was confined to HLA-
matched sibling PBSCT transplants, HLA disparity,
donor relationship, and stem cell source were not in-
cluded in the multivariate analysis. Before introducing
potential time-dependent covariates, such as aGVHD
or cGVHD, into the time-dependent Cox propor-
tional hazard model, we investigated the appropriate-
ness of using a non–time-dependent hazard model
with either aGVHD or cGVHD. In univariate analy-
ses, the P values of the omnibus test (which indicates
a model’s appropriateness in a non–time-dependent
Cox model) were \ .001 for aGVHD and .238 for
cGVHD. Based on this result, we applied cGVHD
only as time-dependent covariate in the model.
In model 1, the following covariates were included
in transplantation outcome (ie, OS, NRM, or relapse)
analysis: cGVHD (time-dependent covariate), age (\
40 years vs $ 40 years), the development of aGVHD
(grade 0-2 vs grade 3-4), disease risk (high risk vs stan-
dard risk), conditioning regimen (myeloablative vs re-
duced intensity),VEGFA1936 C.T genotype (CT vs
the CC genotype), and VEGFA haplotype (2 copies vs
0 or 1 copy of the ACG haplotype). In model 2, VEGF
risk score was adopted instead of VEGFA 1936 C.T
genotype and VEGFA haplotype, to confirm the
VEGF risk score as a surrogate for GVHD risk. The
covariates for aGVHD grade 2-4 or grade 3-4 included
age (\40 years vs$ 40 years), disease risk (high risk vs
standard risk), conditioning regimen (myeloablative vs
reduced intensity), VEGFA1936 C.T genotype (CT
vs the CC genotype), and VEGFA haplotype (2 copies
vs 0 or 1 copy of the ACG haplotype), whereas those
for cGVHD included age (\ 40 years vs $ 40 years),
development of aGVHD (grade 0-2 vs grade 3-4), dis-
ease risk (high risk vs standard risk), conditioning reg-
imen (myeloablative vs reduced intensity), VEGFA
1936 C.T genotype (CT vs CC genotype), and
VEGFA haplotype (2 copies vs 0 or 1 copy of the
ACG haplotype). Multivariate analyses using time-de-
pendent or non–time-dependent Cox proportional
hazard models were conducted using backward-step-
wise modeling and a P value . .05 for the likelihood
ratio test. Hazard ratios (HRs) and 95% confidence in-
tervals (CIs) also were estimated.
Statistic significance was accepted for P values\
.05. Statistical data were obtained using SPSS version
13.0 (SPSS Inc, Chicago, IL), NCSS version 4.0
(NCSS, Kaysville, UT), and the R package (version
2.4.1, available at http://CRAN.R-project.org).RESULTS
Overall Transplantation Outcomes
With a median follow-up of 29.5 months post-
transplantation (range, 0.5 to 74.5 months), 33 patients
Figure 1. Pairwise linkage disequilibrium in the study population. SNPs
selected for haplotype are shown in bold.
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primary disease progression (n 5 15) or NRM (n 5
38). The 2-year OS was 44.3%6 5.3%; cumulative in-
cidences of NRM were 10.8%6 3.6% at 100 days and
24.3%6 5.1% at 2 years, and the cumulative incidence
of recurrence at 2 years was 33.4% 6 5.0%. The cu-
mulative incidences of grade 1-4, grade 2-4, and grade
3-4 severe aGVHD were 81.6% 6 0.2%, 72.2% 6
0.3%, and 39.3% 6 0.5%, respectively, whereas those
of cGVHD were 58.1% 6 5.8% at 6 months and
68.9% 6 5.5% at 2 years.
Genotype Frequencies of the VEGFA
Polymorphisms
The genotype frequencies of the VEGFA polymor-
phisms are summarized in Table 2. All polymorphisms
complied with the HWE (Table 2). The LDs of
VEGFA polymorphisms at loci -2578/-460/1405/
1936 are shown in Figure 1. Strong LDs can be seen
between loci -460 and 1405 (D´ 5 0.94), between
loci -2578 and -460 (D´ 5 1.00), and between loci
-2578 and1405 (D´5 1.00); however, linkages of locus
1936 with -2578 (D´5 0.07), -460 (D´5 0.09), or1405
(D´5 0.13) are weak (D´\0.5). Accordingly, we gener-
ated haplotypes of the VEGFA polymorphisms based
on 3 genotypes at loci -2578, -460, and1405. The fre-
quencies of these haplotypes at loci -2578/-460/1405
were 47.9% for CTC, 26.7% for CTG, 24.2% for
ACG, and 1.0% for CCC.
Univariate Analyses for Factors Associated with
Transplantation Outcomes, Especially aGVHD
On single-marker analysis, the incidence of grade
2-4 aGVHD was higher in patients with the 1936
CT genotype (88%) than in those with the CC geno-
type (64%; P 5 .006; Figure 2A), higher in patients
with the -2578 AA genotype (100%) than in those
with the CA (71%) or CC genotype (73%; P 5
.003), and higher in patients with the -460 CC geno-
type (100%) than in those with the CT (73%) or TT
genotype (73%; P 5 .002). On haplotype analysis,
the incidence of grade 2-4 aGVHD (100%) was higher
in patients with 2 copies of the ACG haplotype than in
those with 0 or 1 copy of this haplotype (68%; P 5
.003; Figure 2B). No association was found between
VEGFA SNPs and the incidence of cGVHD.Table 2. Genotype Frequencies of VEGF Gene Poly-
morphisms at Loci -2578/-460/+405/+936
Allele Ffrequency
Locus % Tested Major Minor HWE P value
-2578 86.2% C: 0.778 A: 0.222 0.303
-460 87.2% T: 0.768 C: 0.232 0.450
+405 100% G: 0.511 C: 0.489 0.038
+936 100% C: 0.819 G: 0.181 0.052With respect to other transplantation outcomes,
patients with the 1936 CT genotype were found to
have a better OS at 2 years than those with the CC ge-
notype (55% vs 38%; P5 .04), but this did not hold for
NRM or recurrence. No differences in terms of OS,
NRM, or recurrence were noted for genotypes at
loci -2578/-460/1405 (Table 3).
VEGF Risk Score Model Predicting the Risk of
aGVHD
Based on the 1936 C.T genotype and VEGFA
haplotype information, we scored VEGFA SNPs based
on the genotype at locus1936 and copy number of the
ACG haplotype at loci -2578/-405/1460. A score of 1
was assigned to risk alleles (ie, 1936 CT or TT geno-
types, or 2 copies of the ACG haplotype), and a score
of 0 was assigned to other alleles (ie, 1936 CC geno-
type, or 0 or 1 copy of the ACG haplotype). After sum-
ming scores, 2 risk groups were defined: high risk
(composite score 2 or 1; n5 37) and low risk (compos-
ite score 0; n5 56). Significant correlations were found
between the incidence of grade 1-4 aGVHD or grade
2-4 aGVHD and the VEGFA SNP score model
(Figure 3A and B). The incidence of grade 2-4
aGVHD was 89% in the high-risk patients (score 1-
2, ie,1936 CT/TT genotype or 2 copies of ACG hap-
lotype) and 62% in the low-risk patients (score 0; ie,
1936 CC genotype and 0 or 1 copy of ACG haplotype)
(P5 .001). No differences were seen between the high-
risk and low-risk patients in terms of OS, NRM, or re-
currence (Table 3).
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Figure 2. VEGFA genotype/haplotype and its association with the risk
of aGVHD. Higher incidences of grade 2-4 aGVHD were observed in pa-
tients with the 1 936 CT genotype (A) or the ACG haplotype for loci
-2578/-460/1405 (B).
Table 3. Transplantation Outcome According to the VEGFAGenot
-2578/-460/+405, and the VEGFA Risk Score
Overall Patients VEGFA +936 C>T Genotype V
(n 5 98)
CT Genotype
(n 5 62)
CC Genotype
(n 5 36) P Value
Follow-up, months 29.5 26 30.5
aGVHD, n (%)
Evaluable patients 93 59 29
Overall 75 (81) 45 (76) 30 (88) .2
Grade 2-4 63 (68) 34 (58) 29 (85) .006
Grade 3,4 26 (28) 16 (27) 10 (29) .8
cGVHD, n (%)
Evaluable patients 74 43 31
Overall cGVHD 54 (73) 30 (70) 24 (77) .6
Extensive cGVHD 30 (41) 16 (37) 14 (45) .6
Survival, n (%)
Relapse 33 (34) 22 (36) 11 (31) .7
Death 53 (54) 37 (60) 16 (45) .1
NRM 38 (39) 27 (44) 11 (31) .3
1412 Biol Blood Marrow Transplant 14:1408-1416, 2008D. H. Kim et al.Organ-Specific Development of aGVHD
According to VEGFA SNPs
We examined the relationships between organ-
specific onset of aGVHD and the VEGFA SNPs.
The VEGFA SNPs, especially the -2578 and -460 ge-
notypes, were found to be closely associated with the
development of gut GVHD (Figure 4), and a higher
risk of gut GVHD was found to be associated with
the -2578 AA genotype (P 5 .04, adjusted P 5 .08;
Figure 4A) or a non-C carrier (P 5 .02, adjusted P 5
.05), as well as with the -460 TT genotype (P5 .05, ad-
justed P5 .07; Figure 4B) or a non-T carrier (P5 .02,
adjusted P 5 .05). Adjustment was performed for age,
conditioning regimen, and disease risk.Multivariate Analysis
Multivariate analysis for the risk of grade 2-4
aGVHD identified 2 risk factors in model 1 (Table 4):
the 1936 CT genotype (P 5 .03; HR 5 1.79; 95%
CI 5 1.07 to 2.99) and the ACG VEGFA haplotype
(P 5 .01; HR 5 3.09; 95% CI 5 1.27 to 7.52). In
model 2, the high-risk group (VEGFA risk score 1 or
2) had a significantly greater risk of aGVHD grade
2-4 (P 5 .001; HR 5 2.32; 95% CI 5 1.41 to 3.81).
The only independent risk factor for grade 3-4 severe
aGVHD was the ACG haplotype (P5 .02; HR5 4.46;
95% CI 5 1.29 to 15.38). Other clinical factors were
not found to be associated with the risk of aGVHD,
perhaps because our cohort included only HLA-
matched sibling PBSCT recipients.
VEGFA SNPs were not found to be associated with
the risk of cGVHD, although a history of a previous
episode of grade 3-4 aGVHD was found to be signifi-
cantly associated with a greater risk of cGVHD (P\
.001; HR 5 3.70; 95% CI 5 1.96 to 6.99). In terms
of overall survival, grade 3-4 aGVHD (P\ .001; HR
5 40.31; 95% CI 5 9.97 to 162.89) and high risk ofype at Position +936 C>T, the VEGFA ACGHaplotype for Loci
EGFA ACG Haplotype at -2578/-460/+405 VEGFA Risk Score
0/1 Copy
(n 5 92)
2 Copies
(n 5 6) P Value
Score 0
(n 5 59)
Score 1-2
(n 5 39) P Value
28.5 53 26.5 30.5
87 6 56 37
69 (79) 6 (100) .6 42 (75) 33 (89) 0.1
57 (66) 6 (100) .08 31 (55) 32 (87) 0.002
23 (26) 3 (50) .3 14 (25) 12 (32) 0.5
69 5 41 33
51 (74) 3 (60) .6 28 (68) 26 (79) 0.4
27 (39) 3 (60) .4 14 (34) 16 (49) 0.2
32 (35) 1 (17) .7 22 (37) 11 (28) 0.4
50 (54) 3 (50) 1.0 37 (60) 16 (45) 0.1
36 (39) 2 (33) 1.0 26 (44) 12 (31) 0.2
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Figure 4. Associations between VEGFA genotypes with the risk of gut
GVHD. The VEGFA -2578C.A (A) and -460T.C genotypes (B) were
found to be associated with the risk of gut GVHD.
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Figure 3. VEGFA risk score model and its association with the risk of
aGVHD. Patients with a VEGFA risk score of 1 or 2 had higher incidences
of aGVHD grade 1-4 (A) or grade 2-4 (B) than those with a VEGFA risk
score of 0.
Biol Blood Marrow Transplant 14:1408-1416, 2008 1413VEGF Gene SNPs and the Risk of Acute GVHDdisease (P5 .001; HR5 6.86; 95% CI5 2.15 to 21.86)
were found to be independent risk factors. With re-
spect to other transplantation outcomes, such as
NRM and relapse, grade 3-4 aGVHD was found to
be significantly associated with a greater risk of
NRM (P\ .001; HR 5 74.02; 95% CI 5 16.58 to
826.21), as was VEGFA 1936C.T genotype (P 5
.01; HR 5 29.43; 95% CI 5 1.99 to 435.24). High-
risk status (P 5 .002; HR 5 3.46; 95% CI 5 1.59 to
7.53) and a previous episode of grade 3-4 aGVHD (P
5 .05; HR5 0.23; 95% CI5 0.05 to 0.97) were found
to be independent predictors of relapse after allogeneic
transplantation.DISCUSSION
The results of the present study suggest an associ-
ation between VEGFA SNPs and a lower risk of
aGVHD after allogeneic SCT (especially gut
GVHD), as well as a protective role for VEGF in the
pathogenesis of aGVHD. VEGF exerts 2 actions inthis respect: a proinflammatory effect that may pro-
voke inflammatory reactions in target tissues [25] and
an angiogenic effect that may facilitate tissue reperfu-
sion and regeneration in inflamed tissues [26]. Conse-
quently, VEGF may have a protective or augmentative
role in the pathogenesis of GVHD in opposite direc-
tions; elevated VEGF could either increase the severity
of GVHD by promoting inflammation or reduce the
severity of GVHD by stimulating tissue perfusion.
Our findings suggest that VEGF may protect
against the development of severe GVHD, in agree-
ment with previous reports associating elevated
VEGF levels on day 14 or 15 posttransplantation
with decreased risk of severe aGVHD and NRM
[4,6] Whether VEGF up-regulation is a consequence
of tissue hypoxia in GVHD or whether it acts as a me-
diator of endothelial regeneration by inhibiting irre-
versible fibrosis caused by cytotoxic T lymphocytes is
unclear, however. Regardless, it is apparent that high
Table 4. Multivariate Analysis of aGVHD or cGVHD and Transplantation Outcomes
Risk Factor HR (95% CI) P value
aGVHD, grade 2-4
Model 1*
+936 C>T VEGFA genotype CC genotype 1.00 .03
CT genotype 1.79 (1.07 to 2.99)
ACG VEGFA haplotype 0 or 1 copy of ACG haplotype 1.00 .01
2 copies of ACG haplotype 3.09 (1.27 to 7.52)
Model 2†
VEGFA risk score Score 0 1.0 .001
Score 1 to 2 2.32 (1.41 to 3.81)
aGVHD, grade 3-4*
ACG VEGFA haplotype 0 or 1 copy of ACG haplotype 1.00 .02
2 copies of ACG haplotype 4.46 (1.29 to 15.38)
cGVHD‡
aGVHD aGVHD, grade 0-2 1.00 < .001
aGVHD, grade 3-4 3.70 (1.96 to 6.99)
NRM§
aGVHD aGVHD, grade 0-2 1.00 .003
aGVHD, grade 3-4 4.15 (1.65 to 10.53)
Relapse§
aGVHD aGVHD, grade 0-2 1.00 .05
aGVHD, grade 3-4 4.386 (1.027 to 18.729)
Disease risk Standard risk 1.00 .002
High risk 3.46 (0.133 to 0.627)
*Age, disease risk, conditioning regimen, VEGFA +936 C>T genotype, and VEGFA ACG haplotype were included in the analysis.
†Age, disease risk, conditioning regimen, and VEGFA risk score were included in the analysis.
‡Age, development of aGVHD, disease risk, conditioning regimen, VEGFA +936 C>T genotype, and VEGFA ACG haplotype were included in the analysis.
§Age, development of aGVHD or cGVHD, disease risk, conditioning regimen, VEGFA +936 C>T genotype, and VEGFA ACG haplotype were included in
the analysis.
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On the other hand, a study in a murine model con-
cluded that VEGF has a proinflammatory function in
the alloimmunity setting [27]. In the murine renal allo-
graft model used in that study, anti-VEGF antibody
was found to markedly inhibit T cell infiltration into
allografts and acute rejection, and thus it was con-
cluded that VEGF exerts robust proinflammatory ac-
tivity in the alloimmunity setting [27]. But the renal
allograft environment in a murine model likely differs
greatly from that in a human GVHD setting. Accord-
ingly, further studies are warranted to clarify this issue,
and to determine whether VEGF is a driver or passen-
ger in the development of GVHD.
Similarly, studies of VEGF in inflammatory bowel
disease (IBD) suggest that VEGF has proinflammatory
activity, with VEGF expression found to be higher in
patients with IBD than in healthy controls and to be
positively correlated with disease activity [28,29].
These results are at odds with our finding that lower
VEGF production is associated with a higher risk of
gut GVHD. But microvessel densities are attenuated
in GVHD tissues [1] but elevated in IBD [30], and
thus we postulate that although gut GVHD and IBD
share similar pathogenetic mechanisms and pathologi-
cal findings, VEGF’s proinflammatory activity is more
prominent during the pathogenesis of IBD, whereas its
angiogenic activity is more significant in GVHD.
Genetic variations in the genes encoding these
molecules may affect transcription and translation ormay modulate the functions of the gene products.
Growing evidence supports the notion that cytokine
gene polymorphisms are important predictors of
transplantation-related complications, including
aGVHD and cGVHD, and transplantation outcomes
[15,31-33]. For example, it is generally accepted that
the SNPs of proinflammatory cytokines, such as inter-
leukin (IL)-1, IL-2, IL-6, interferon-g, or tumor ne-
crosis factor-a, and of anti-inflammatory cytokines,
such as IL-10, affect transplantation outcomes, includ-
ing aGVHD and cGVHD and transplantation-related
mortality [15].
In the present study, patients with the 1936 CT
genotype were found to have a higher risk of grade
2-4 aGVHD than patients with the CC genotype
(88% vs 64%; P 5 .006; Figure 2A). In addition,
patients with 2 copies of the ACG haplotype were
found to have a higher risk of grade 2-4 aGVHD
than patients with 0 or 1 copy of the ACG haplotype
(100% vs 68%; P5 .003; Figure 2B). Furthermore, ac-
cording to our risk score model, the incidence of grade
2-4 aGVHD was 89% in the high-risk patients (score
1-2, ie, 1936 CT genotype or any ACG haplotype),
compared with 62% in the low-risk patients (P 5
.001; Figure 3B). However, a limitation of the current
study is the very low number of high-risk patients (ie,
6). Accordingly, further studies are needed with larger
numbers of patients to enable a clear conclusion on
this issue.
In terms of the specific effects of the VEGFA geno-
types, the1936 CT genotype and the ACG haplotype
Biol Blood Marrow Transplant 14:1408-1416, 2008 1415VEGF Gene SNPs and the Risk of Acute GVHD(for loci -2578/-460/1405) appeared to reduce VEGF
production. In our previous study of patients with
acute myeloid leukemia (AML), those patients with
the 1936 CC genotype and CTG haplotype had
a higher risk of relapse, and this was associated with
VEGF up-regulation. Conversely, the 1936 CT ge-
notype and the ACG haplotype were associated with
VEGF down-regulation. Previous studies also have
found an association between the 1936T allele in
the 1936C.T genotype and VEGF down-regulation
[10,34]. VEGF expression differences caused by
VEGFA SNPs may be due to (1) a loss of a potential
binding with the transcription factor AP-4 in the
presence of the C-to-T transition; (2) LD of the poly-
morphism with another, as-yet unidentified polymor-
phism; or (3) modification of the mRNA structure
[10]. In the present study, we did not perform pro-
moter assays to evaluate the functional role of VEGFA
haplotypes; however, a previous study in a Korean
population with the TG haplotype at loci -460/1405
suggested an association between the TG haplotype
at loci -460/1405 and VEGF up-regulation [17].
In conclusion, our findings support the notion that
VEGF protects against aGVHD, especially against the
development of severe aGVHD. They also suggest
that VEGFA polymorphisms can be used to predict
the risk of aGVHD.ACKNOWLEDGMENTS
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